Benzodiazepine analogs

A method of treating panic disorder or anxiety disorder in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of the formula:

• ##STR74## wherein R.sup.1 is --NR.sup.16 R.sup.17,;
• R.sup.2 is H, loweralkyl, substituted or unsubstituted phenyl (wherein the substituents are 1 or 2 of halo, loweralkyl, loweralkoxy, loweralkylthio, carboxyl, carboxyloweralkyl, nitro, --CF.sub.3, or hydroxy), 2-, 3-, 4-pyridyl, --X.sup.12 COOR.sup.6, ##STR75## R.sup.3 is --X.sup.11 R.sup.7, ##STR76## R.sup.4 and R.sup.5 are independently R.sup.6 or in combination with the N of the NR.sup.4 R.sup.5 group form an unsubstituted or mono or disubstituted, saturated or unsaturated, 4-7 membered heterocyclic ring, or benzofused 4-7 membered heterocyclic ring or said heterocyclic ring or said benzofused heterocyclic ring which further comprises a second heteroatom selected from O and NCH.sub.3 and the substituent(s) is/are independently selected from C.sub.1-4 alkyl;
• R.sup.6 is H, loweralkyl, cycloloweralkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted phenylloweralkyl (wherein the substituents are 1 or 2 of halo, loweralkyl, loweralkoxy, nitro, or CF.sub.3);
• R.sup.7 is .alpha.- or .beta.-naphthyl, substituted or unsubstituted phenyl (wherein the substituents are 1 to 2 of halo, --NO.sub.2, --OH, --X.sup.11 --NR.sup.4 R.sup.5, loweralkyl, loweralkoxy, CF.sub.3), loweralkylthio, cyano, phenyl, acetylamino, acetoxy, SCF.sub.3, C.tbd.CH, CH.sub.2 SCF.sub.3, OCHF.sub.2, ##STR77## with the proviso that q is not 0 in ##STR78## R.sup.8 is H, loweralkyl, cycloloweralkyl, --X.sup.12 CONH.sub.2, --X.sup.12 COOR.sup.6, --X.sup.11 -cycloloweralkyl, --X.sup.12 NR.sup.4 R.sup.5, ##STR79## R.sup.11 and R.sup.12 are independently loweralkyl or cycloloweralkyl;
• R.sup.13 is O;
• R.sup.14 is loweralkyl or phenylloweralkyl;
• R.sup.16 and R.sup.17 are, when separate, independently H, loweralkyl, lower alkenyl, --X.sup.11 cycloloweralkyl, --X.sup.12 --NR.sup.4 R.sup.5, X.sup.12 CONR.sup.4 R.sup.5, --X.sup.12 C.tbd.N, ##STR80## --X.sup.12 COOR.sup.6, or --CN;
• or, when joined, form with N, a heterocycle ##STR81## wherein n' is 2-6;
• R.sup.18 is H or loweralkyl;
• p is 0 or 1;
• q is 0-4;
• r is 1 or 2;
• X.sup.1 is H, --NO.sub.2, CF.sub.3 CN, OH, loweralkyl, halo, loweralkylthio, loweralkoxy, --X.sup.11 COOR.sup.6 or --X.sup.11 NR.sup.4 R.sup.5 ;
• X.sup.2 and X.sup.3 are independently H, --OH, --NO.sub.2, halo, loweralkylthio, loweralkyl or loweralkoxy;
• X.sup.4 is S, O, CH.sub.2 or NR.sup.8 ;
• X.sup.5 is H, CF.sub.3, CN, COOR.sup.6, NO.sub.2, or halo;
• X.sup.6 O or HH;
• X.sup.8 is H or loweralkyl;
• X.sup.9 and X.sup.9.sub.a are independently NR.sup.18, O;
• X.sup.11 is absent or C.sub.1-4 linear or branched alkylidene;
• X.sup.12 is C.sub.1-4 linear or branched alkylidene;
• or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.